Search

ABSTRACT A simple procedure enables to obtain a hole-containing PPy film on SAE 4140 steel in sodium bis(2-ethylhexyl) sulfosuccinate (AOT) solutions. The film characterization was made by electrochemical and morphological studies. The effects of electropolymerization parameters on the obtained morphology are discussed. The formation of the coating is conditioned by the nature of the substrate and surfactant and the electrochemical technique employed. Electrochemical investigations demonstrate that the hole-containing PPy film presents an increase in surface area. The polymer was modified by cementation of copper particles. The modified polymer offers a higher electrocatalytic activity for the HER than usual PPy. © 2016 Wiley Periodicals, Inc. J. Appl. Polym. Sci. 2016, 133, 43650. [ABSTRACT FROM AUTHOR]

Based on a murine model, we conducted a series of trials of m-myeloablative human leucocyte antigen (HLA)-matched or mismatched related donor stem cell transplantation (SCT) with the intention of inducing mixed chimaerism (MC), then administering prophylactic donor lymphocyte infusions (DLIs), for the treatment of advanced haematologic malignancies. Preparative therapy consisted of cyclophosphamide, equine anti-thymocyte globulin (ATG) or MEDI-507 (an anti-CD2 monoclonal antibody) for in-vivo T-cell depletion, thymic irradiation on day -1 and cyclosporine alone for graft-versus-host disease (GVHD) prophylaxis. DLIs were given as early as 5 weeks post-SCT in patients with MC without evidence of GVHD. Twenty-two patients ultimately lost their graft (<1% donor cells) that could no be rescued by DLIs. Nine of 22 (41%) patients who lost donor chimaerism achieved an objective response, including three patients who showed evidence of disease regression following DLI, despite continued absence of macrochimaerism. Six patients were alive at 2.5-5.5 years following SCT, including four in continuous complete remission. In summary, it is possible to achieve sustained remission in patients with chemorefractory malignancies following non-myeloablative allogeneic SCT, even in the absence of sustained donor macrochimaerism; DLI may contribute to an ongoing anti-tumour effect in these patients. Immunological mechanisms that correlated with rejection of the graft may have a role in anti-tumour responses via a cell or cytokine-mediated pathway.